Roots Analysis

MARCH 13, 2022

In the last decade alone, the annual number of approvals of biopharmaceuticals (including monoclonal antibodies, recombinant proteins, vaccines and gene therapies), by the US FDA, have steadily risen. Over the years, the rising popularity of biologics has led to a paradigm shift in the healthcare industry.

Manufacturing 52

Manufacturing Drug Delivery Marketing Drug Delivery Systems 52

Delveinsight

JULY 30, 2020

A novel, brain penetrant, orally bioavailable and selective PPAR? Magenta Therapeutics , a clinical-stage biotechnology company is evaluating its one-time cell therapy, MGTA-456 for the treatment of multiple inherited metabolic disorders, which has received Regenerative Medicine Advance Therapy (RMAT) designation from the US FDA.

Hormones 52

Hormones Marketing Gene Trials 52

XTalks

AUGUST 30, 2022

We know that a lot of different pathologies, especially as we’ve entered the era of molecular medicine and gene therapies, cause many of the same symptoms and work through final common pathways. However, a drawback is that the dose and neuronal specificity of gene therapy is still poorly understood even in translational models.

Trials 83

Trials Drug Delivery Drugs Gene 83